Mineralys Therapeutics is a publicly traded, clinical-stage biotechnology company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that we are developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease.
Mineralys is a fully remote company.
For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn.
Sim — a Mineralys Therapeutics tem 340 vagas em aberto no JobsRadar neste momento. 308 delas foram abertas nos últimos 30 dias. 340 delas divulgam salário, com uma mediana de $147,500 por ano. 1 foram adicionadas nas últimas 24 horas; última atualização a 24 de julho de 2026 às 15:00 UTC.